Overview
- The New England Journal of Medicine–published interim analysis of the Phase 1b Heart‑2 trial, disclosed Monday, reported dose‑dependent reductions in circulating PCSK9 protein (up to 88%) and LDL cholesterol (up to 62%) after one intravenous infusion of VERVE‑102.
- VERVE‑102 uses in vivo base editing delivered in a GalNAc‑ligand lipid nanoparticle that sends mRNA encoding an adenine base editor plus a guide RNA to liver cells to permanently inactivate the PCSK9 gene.
- The interim safety profile was encouraging with no treatment‑related serious adverse events or dose‑limiting toxicities reported but included mild infusion reactions, transient ALT elevations, and one unrelated serious event, and investigators say longer follow‑up is required to assess long‑term risks such as off‑target editing.
- Regulators gave VERVE‑102 Fast Track status for LDL reduction and Eli Lilly plans a larger Phase 2 trial this year while the Heart‑2 study continues to follow participants for durability of effect up to about 18 months in some people.
- If larger, longer trials confirm safety and show fewer heart attacks or strokes, a one‑time PCSK9 base‑editing therapy could shift care from chronic pills and injections to a durable intervention, but questions remain about long‑term outcomes, patient selection, manufacturing scale and cost.